Formative Evaluation for Shigellosis Sexual Health Materials for Men Who Have Sex with Men

Generic Information Collection (0920-1154)

Supporting Statement Part A

Submitted: May 8, 2017

Program Official/Project Officer

Matt Karwowski

Division of Foodborne, Waterborne, and Environmental Diseases, NCEZID

1600 Clifton Rd, NE, Mailstop C-09

404-718-5867

ydh4@cdc.gov

Table of Contents

1.	CIRCUMSTANCES MAKING THE COLLECTION OF INFORMATION NECESSARY
2.	PURPOSE AND USE OF INFORMATION COLLECTION
3.	USE OF IMPROVED INFORMATION TECHNOLOGY AND BURDEN REDUCTION
4.	EFFORTS TO IDENTIFY DUPLICATION AND USE OF SIMILAR INFORMATION
5.	IMPACT ON SMALL BUSINESSES OR OTHER SMALL ENTITIES
6.	Consequences of collecting the information less frequently7
7.	Special circumstances relating to the guidelines of 5 cfr 1320.57
8. Outsi	Comments in response to the federal register notice and efforts to consult de the agency
9.	EXPLANATION OF ANY PAYMENT OR GIFT TO RESPONDENTS7
10. respo	PROTECTION OF THE PRIVACY AND CONFIDENTIALITY OF INFORMATION PROVIDED BY NDENTS
11.	INSTITUTIONAL REVIEW BOARD (IRB) AND JUSTIFICATION FOR SENSITIVE QUESTIONS8
12.	ESTIMATES OF ANNUALIZED BURDEN HOURS AND COSTS
13. keepe	ESTIMATES OF OTHER TOTAL ANNUAL COST BURDEN TO RESPONDENTS OR RECORD RS
14.	ANNUALIZED COST TO THE GOVERNMENT
15.	EXPLANATION FOR PROGRAM CHANGES OR ADJUSTMENTS
16.	Plans for tabulation and publication and project time schedule
17.	REASON(S) DISPLAY OF OMB EXPIRATION DATE IS INAPPROPRIATE
18.	EXCEPTIONS TO THE CERTIFICATION FOR PAPERWORK REDUCTION ACT SUBMISSIONS10
19.	References11

List of Attachments

- 1. Authorizing Legislation
- 2. Screener
- 3. Recruitment Script
- 4. Focus Group Moderator Guide Phase 1
- 5. Informed Consent
- 6. CDC IRB Letter

- The goals of the formative evaluation are to assess the knowledge, perceptions, and behaviors of men who have sex with men regarding *Shigella* infections, as well as to obtain feedback on initial health messaging to develop sexual health materials for MSM.
- Results of the evaluation will be used to inform the development of shigellosis prevention materials for MSM. Materials to be developed from results include: campaign concepts, messages, and materials to motivate MSM to prevent multidrug-resistant *Shigella* infections and be alert to shigellosis through early detection of infections.
- This qualitative formative evaluation will use stratified, non-probability purposive sampling to recruit consumers for focus groups (FGs). We will recruit potential respondents by advertising the evaluation through various community and social media outlets as well as health care and social service providers serving the LGBT community in Georgia. Passive recruitment will occur through these partners via printed materials that describe the evaluation and direct interested participants to call the evaluation telephone number. We will also incorporate the snowball method of recruitment, in which callers are asked to share the evaluation's contact information with their network. All participants will reside in Georgia.
- The MSM FGs will be stratified by: race (African American, Hispanic, and Caucasian) and HIV-status.
- Data analysis: Qualitative data will be analyzed using thematic or grounded theory analysis that will identify relevant, common, and cross-cutting themes within FG responses in order to summarize participants' knowledge, perceptions, and behaviors regarding shigellosis and its prevention.

1. Circumstances Making the Collection of Information Necessary

The Centers for Disease Control and Prevention (CDC) is requesting approval for a new generic information collection (gen-IC), "Formative Evaluation for the Shigellosis Sexual Health Materials for Men Who Have Sex with Men."

This information collection involves formative evaluation to understand the knowledge, perceptions, and behaviors of men who have sex with men regarding *Shigella* infections, as well as to obtain feedback on initial health messaging to develop sexual health materials for MSM. This information collection uses qualitative data consisting of focus group discussions.

This information collection is authorized by Section 301 of the Public Health Service Act (42 U.S.C.241) (Attachment 1).

Shigellosis is a nationally notifiable disease with an annual estimated incidence of 500,000 cases in the United States [1]. *Shigella* infections are characterized by diarrhea, fever, and stomach cramps, starting 1 to 4 days after exposure to shigellae, and lasting between 5 and 7 days after symptom onset. An estimated 20% of shigellosis patients are hospitalized, and about 40 shigellosis-related deaths occur each year [2]. Shigellosis has a very small infectious dose and is transmitted through the fecal-oral route. This can happen when an infected or convalescent patient contaminates food, beverages, or water that is then ingested by another person, through person-to-person contact that results in unintended transfer of shigellae to the hands of another

person, through contamination of objects with shigellae that are later unintentionally ingested, or through sexual activity. Shigellosis is most commonly transmitted from person-to-person among young children and their caretakers; however, many outbreaks have recently been documented among MSM [3-6]. Furthermore, shigellosis may be more severe, and shedding of shigellae in stool may be prolonged, among HIV-infected MSM [7].

Multidrug-resistant (MDR) shigellosis is emerging in the United States. Shigellosis patients frequently are treated with antimicrobial medications to reduce illness duration and to attempt to reduce transmission. Over the last several years, high rates of resistance to ampicillin and trimethoprim/sulfamethoxazole have made ciprofloxacin, ceftriaxone, and azithromycin the preferred antimicrobial agents for adults and children with shigellosis; ceftriaxone is also the preferred treatment for invasive shigellosis [8-10]. Recently, shigellae resistant to these preferred antimicrobials have emerged in the United States and abroad [3, 5, 11-18], and in 2013 CDC declared MDR shigellosis a serious threat in the United States [19]. Although shigellosis is most commonly reported in children <5 years old [20], most reports document ciprofloxacin- or azithromycin-resistant shigellosis clusters appear to be 3–77 times more likely to be resistant to preferred antimicrobials than clusters with non-sexual transmission routes [24].

Shigellosis has been linked repeatedly to sexual behavior during recent decades. Rates of *S*. *flexneri* infection began increasing among U.S. adult males in the 1970s, particularly among men 20 – 39 years old, but remained stable or decreased in other demographic groups [25]. A population-based case-control study in San Francisco found shigellosis was strongly associated with MSM, HIV infection, and direct oral-anal contact [21]. Recent shigellosis cases in the United Kingdom also related to sexual practices. From January 2009 to October 2012, 37 of 38 S. flexneri cases in the UK were among men; 36 (97%) self-identified as MSM. Of the 36 MSM, 88% were known to be HIV-infected, 58% reported at least one casual male partner during the previous month, and seven (62%) recalled oral-anal contact [26]. Moreover, during an outbreak in Australia among 98 MSM, visiting a sex venue in the 2 weeks before onset of illness was the only identified risk factor [27]. Several gualitative studies corroborate the association between shigellosis and sexual behavior. One study of 42 men aged \geq 18 years who were diagnosed with shigellosis between October 2012 and May 2013 found that 34 (81%) were sexually active MSM, of whom many reported meeting casual sexual partners through social media outlets or using recreational drugs during sex, which may have increased risky sexual behaviors [28]. Despite the data linking shigellosis to sexual behavior during recent decades, few data exist to guide shigellosis prevention campaigns among the MSM population, and campaigns to prevent transmission of sexually transmitted non-enteric infections may not fully apply to prevention of shigellosis among MSM.

Shigellosis prevention materials will require not only clearer understanding of shigellosis knowledge, attitudes, and perceptions among MSM, but also creativity that accounts for wariness of sexual health messaging in this population. Since the beginning of the HIV epidemic, HIV prevention messaging has targeted MSM, as one of the most at risk populations in the United States. HIV prevention initiatives have been associated with effective risk reduction among most at risk populations, including MSM [29]. Over the past decade, however, rates of HIV and sexually transmitted infections among some groups of MSM appear to be increasing [30-32].

Some researchers attribute this resurgence to boredom or psychological resistance to HIV prevention messages resulting from repeated exposure [33, 34]. Researchers have continued to study the effectiveness of HIV prevention messaging, most recently in light of the clinical effectiveness of pre-exposure prophylaxis (PrEP) [35, 36], and found that MSM, regardless of HIV status, view PrEP and condoms as effective and important tools to prevent HIV. However, both HIV negative and HIV positive MSM do not accept that assertion of an undetectable viral load mitigates HIV transmission, and HIV negative MSM's attitude regarding treatment as prevention leans significantly more toward "strongly disagree" than their HIV positive counterparts [37]. In addition, some MSM see PrEP as an "excuse," or rather means to forgo condoms [38]; and, this perception appears to be corroborated by sexually transmitted disease infection rates among MSM on PrEP [30-32]. Among MSM of color, those at greatest risk for HIV, a recent study on attitudes toward PrEP and condoms found that Latinos favor condoms over PrEP, while African American MSM prefer the increased level of protection offered by combining PrEP with condoms [39]. That is, recent research reveals critical variation in attitudes and receptiveness to prevention messages mediate the effectiveness of prevention efforts across different communities of MSM [40, 41]. More generally, prevention research further suggests that successful prevention messaging includes several key elements: 1) prevention messages must appeal to the targeted community [42], 2) the messages should be brief [43, 44]; and 3) multiple messages are most effective [45]. In sum, when attempting to convey information to or motivate at-risk communities to take action, the messaging should appeal to the community. briefly state the case, and involve a series of messages that convey the intended point(s).

2. Purpose and Use of Information Collection

Given the increasing rates of shigellosis among MSM, and the unknown knowledge and awareness among MSM regarding shigellosis and its prevention, CDC is proposing to create health materials aimed at informing MSM about shigellosis and preventing infections. The goal of creating health materials for MSM is to raise awareness of shigellosis and its prevention among MSM who are most at risk for antibiotic resistant shigellosis.

The Shigellosis Sexual Health Materials for MSM goals are to:

- Raise awareness and knowledge of shigellosis among MSM to prompt shigellosis prevention and early recognition.
- Decrease cases of multidrug-resistant shigellosis.
- Support CDC's contributions to the National Strategy to Combat Antibiotic Resistance: <u>https://www.cdc.gov/drugresistance/federal-engagement-in-ar/national-strategy/</u> <u>index.html</u>

The primary evaluation questions in phase one are:

- 1. Where do MSM go for health related questions?
- 2. What sources do MSM trust for health information?
- 3. What are MSM's preferred ways (message, channel, and source) to obtain information about sexual health?
- 4. What are MSM's general awareness about shigellosis?
- 5. What do MSM know about shigellosis?

- a. What are perceptions (beliefs or general thoughts) about shigellosis (e.g., the severity of shigellosis)?
- 6. Before having sex, do MSM discuss if they recently had diarrhea?
- 7. Do MSM believe they are at risk for shigellosis?
- 8. How do MSM seek information about sexual health?
- 9. What are MSM's reactions to initial sexual health message sets?

Following completion of the phase one formative research, a second round of information collection will be done. Phase two will consist of health message testing and will be submitted to OMB for review separately using CDC's health message testing generic package (0920-0572).

MSM will be screened for eligibility prior to recruitment for the focus groups. Exhibit 1 provides an overview of the data collection activities.

Instruments						
Recruitment The recruitment screener will be used to determine eligibility and recruit						
Screener	appropriate MSM for focus groups. The screener will request demographic					
(Attachment 2)	ent 2) information, inclusion criteria, and willingness to participate in focus groups. T					
	screener will be administered by telephone by an investigator from Georgia State					
	University and takes 5 minutes to complete.					
Participant Georgia State University will recruit potential respondents by advertising the						
Recruitment	cruitment evaluation through various community and social media outlets as well as health					
Script	Script care and social service providers serving the LGBT community in Georgia. Passi					
(Attachment 3)	recruitment will occur through these partners via printed materials that describe the					
	evaluation and direct interested participants to call the evaluation telephone number.					
	We will also incorporate the snowball method of recruitment, in which callers are					
	asked to share the evaluation's contact information with their network. All data					
	collected as part of screening is subject to confidentiality and human subject					
	protections.					
Focus Group	We will conduct six focus group discussions, each lasting up to one hour or until we					
Moderator	reach the point of saturation. Focus groups will allow us to determine the					
Guide	knowledge and perceptions of MDR shigellosis infections and shigellosis					
(Attachment 4)	prevention among MSM, and to assess preferences for the tone and format of					
	shigellosis prevention materials. These discussions will be led using a phase-					
	specific focus group moderators' guide.					

Exhibit 1. Data Collection Activities

3. Use of Improved Information Technology and Burden Reduction

Data will be collected via focus groups discussions at Georgia State University. A note taker will be present to take notes for each focus group; all focus groups will be recorded to ensure participant responses are captured accurately. Items on the focus group moderators have been limited to only those relevant to the target audience to reduce burden on respondents.

4. Efforts to Identify Duplication and Use of Similar Information

To date, there has been no research conducted that has attempted to identify MSMs awareness of shigellosis.

5. Impact on Small Businesses or Other Small Entities

Georgia State University investigators anticipate MSMs participation in focus groups will be conducted at times that would not impact their employment in a small business or small entity (if applicable). We will provide flexibility in scheduling focus groups to minimize the potential impact on small businesses and other small entities.

6. Consequences of Collecting the Information Less Frequently

This is a one-time information collection request.

7. Special Circumstances Relating to the Guidelines of 5 CFR 1320.5

There are no special circumstances with this information collection package. This request fully complies with the guidelines in 5 CFR 1320.5 and will be voluntary.

8. Comments in Response to the Federal Register Notice and Efforts to Consult Outside the Agency

A. This information collection request does not require publication of a 60-day notice in the *Federal Register*.

B. CDC has been working with Georgia State University investigators on the design, instrumentation, and initial message sets for this evaluation. Several CDC experts provided input on target audiences, instrument content, and initial message sets developed by Georgia State University investigators.

Individuals consulted outside the agency include:

- Eric Wright, Georgia State University (404) 413-6527
 <u>ewright@gsu.edu</u>
- Ebony Townshed, Georgia State University Etownsend1@student.gsu.edu

9. Explanation of Any Payment or Gift to Respondents

Focus group participants will receive a monetary gift of appreciation for their participation. It is assumed that many of these participants will be taking time either during work hours or personal time to complete the focus groups, and may have children. Therefore the monetary gift may serve to offset costs related to participating in the evaluation in the amount of \$40 for participation in 60-minute focus group.

10. Protection of the Privacy and Confidentiality of Information Provided by Respondents

The CDC Human Subjects Advisor has determined that the Privacy Act does not apply to this information collection. Focus groups participants will be recruited and moderated by Georgia State University investigators. CDC will not have direct contact with participants or access to any personally identifying information (PII) about the participants and PII will not be linked to responses.

PII (e.g., name, address, e-mail address, and telephone number) will be used by Georgia State University to make contact with and send reminders to respondents. This information will be kept separate from any information collected in the focus groups (i.e., participant responses will not be connected to any identifiable information). Screeners will be kept in a locked file cabinet at Georgia State University or in password-protected computer files. The recruiter will only provide a summary of participant information on the recruitment grids, which will be stripped of PII. No PII will be transmitted to CDC. Georgia State University investigators will be instructed to destroy their project-related records upon completion of the evaluation.

All findings will be reported in the aggregate only. The contractor will take precautions to secure participants' identifiable information (see Attachment 6). Participants will use only first names or pseudonyms during the discussions. Notes will not include participants' names. Audio files of the groups will be stored by Georgia State University investigators on a secure share drive and password-protected computers. Reports will not include PII and will be stored on a secure share drive and password-protected computers.

11. Institutional Review Board (IRB) and Justification for Sensitive Questions

Institutional Review Board (IRB)

To ensure the privacy of data compiled for the protection of human subjects, the data collection protocol and instruments were reviewed and approved through CDC's Institutional Review Board (IRB) (Attachment 7). This review ensures compliance with the spirit and letter of HHS regulations governing such projects.

Justification for Sensitive Questions

The majority of questions asked will not be of a sensitive nature. All participants will be informed that they need not answer any question that makes them feel uncomfortable or that they simply do not wish to answer (Attachment 6). To address any concerns about inadvertent disclosure of sensitive information, respondents will be fully informed of the applicable privacy safeguards.

12. Estimates of Annualized Burden Hours and Costs

Table 1 below describes the burden associated with the information collection.

The burden estimate for the moderator guide includes the burden to review the informed consent, which will be completed by Georgia State University investigators.

Type of Responden t	Form Name	No. of Respondents	No. of Responses per Respondent	Average Burden Per Response (hours)	Total Burden Hours
MCM	Screener	400	1	5/60	34
IVISIVI	Moderator Guide	45	1	1	45
Total					79

Table 1. Annualized Burden

Table 2 below describes the cost burden associated with this information collection. It was calculated based on the hourly wage rate for "all occupations" in the Bureau of Labor Statistics May 2015 National Occupational Employment and Wage Estimates (BLS, 2015) and from the U.S. Department of Labor Federal Minimum Wage Standards.

Type of Respondent	Form Name	Total BurdenHourly WageHoursRate		Total BurdenHourly WageHoursRate		Total Respondent Costs	
	Screener	34	\$23.23	\$789.82			
MSM	Moderator Guide	45	\$23.23	\$1,045.35			
Total				\$1,835.17			

13. Estimates of Other Total Annual Cost Burden to Respondents or Record Keepers

There will be no direct costs to the respondents other than their time to participate in each information collection.

14. Annualized Cost to the Government

The total annualized cost to the government is \$43,892 and consists entirely of federal staff time on the project.

Governmental costs for this project include personnel costs for federal staff involved in the plan and data collection design, development of data collection instruments and OMB materials, data collection and analysis, and reporting. This level of effort includes approximately 10 percent of a GS-11 health scientist's time for each campaign assuming a \$60,400 annual salary (total \$6,040), and 50 percent time of a GS-12 behavioral scientist assuming a \$75,705 annual salary (total \$37,852). The seed grant award will cover the majority of the costs, thus, the total cost to the government consists of the federal staff's time in the amount of \$43,892.

15. Explanation for Program Changes or Adjustments

This is a new information collection.

16. Plans for Tabulation and Publication and Project Time Schedule

Data will be tabulated and a report will be developed. Qualitative findings may be published in a peer-reviewed journal article.

Project Time Schedule

Recruitment, focus groups, data analyses, and creation of health promotion materials will be time consuming and take two years to complete.

PROJECT TIMELINE		Year 1			Year 2			
	1 st	2 nd	3 rd	4 th	1 st	2 nd	3 rd	4 th
Task	Q	Q	Q	Q	Q	Q	Q	Q
IRB submission (CG)								
Create Focus Group Discussion Guide (CG)								
Recruit Focus Group Respondents (G)								
Conduct Phase 1 Focus Groups (G)								
Transcribe/Analyze Phase 1 Focus Group Data (C)								
Prepare Progress Report (CG)								
Develop Prevention Messages and Creative Concepts								
(CG)								

Principal Partner(s) Responsible: (C) CDC; (G) GSU; (CG) Both

Analysis

Thematic or grounded theory analysis of the focus group data collected in phase one will help us understand MSM's knowledge of MDR shigellosis and its prevention, perceptions of MDR shigellosis, and motivation to prevent these infections. Focus group data will be transcribed in a Word document, then uploaded to NVivo for applying the thematic or grounded theory analytic frame.

Dissemination of results and applications for future funding.

We will use our findings to develop and disseminate health promotion materials to help prevent sexual transmission of MDR shigellosis infections.

The results of this evaluation will be summarized and shared publically, such as through scientific meetings and peer-reviewed publications. Shigellosis prevention materials developed during this project will be made freely available through the CDC website and will be shared with state and local public health departments and other partners serving LGBT communities. These materials will help inform MSM about preventing sexual transmission of MDR shigellosis.

It is expected that our findings will assist public health departments and other groups as they create messaging around prevention of sexual transmission of other enteric infections, particularly those predominately found among MSM.

Finally, the findings from this evaluation will be used to develop future grant proposals to expand this evaluation program. Depending on the nature of the findings, we anticipate submitting one or more funding applications to the NIH and/or other community foundations dedicated to improving the sexual health and reduce STDs among MSM to further develop the prevention materials identified and identify best practices for integrating shigellosis-related prevention efforts within ongoing prevention initiatives focused on other STDs and HIV.

17. Reason(s) Display of OMB Expiration Date is Inappropriate

The expiration date of OMB approval will be displayed on all information collection instruments.

18. Exceptions to the Certification for Paperwork Reduction Act Submissions

There are no exceptions to the certification. These activities comply with the requirements in 5 CFR 1320.

19. References

Scallan E, Hoekstra RM, Angulo FJ, Tauxe RV, Widdowson MA, Roy SL, Jones JL, Griffin PM.
Foodborne illness acquired in the United States--major pathogens. Emerg Infect Dis. 2011;17(1):7-15.
Scallan E, Mahon BE. Foodborne Diseases Active Surveillance Network (FoodNet) in 2012: a foundation for food safety in the United States. Clin Infect Dis. 2012;54 Suppl 5:S381-4

3. Bowen A, Eikmeier D, Talley P, Siston A, Smith S, Hurd J, Smith K, Leano F, Bicknese A, Norton JC, Campbell D, Centers for Disease C, Prevention. Notes from the Field: Outbreaks of Shigella sonnei Infection with Decreased Susceptibility to Azithromycin Among Men Who Have Sex with Men - Chicago and Metropolitan Minneapolis-St. Paul, 2014. MMWR Morb Mortal Wkly Rep. 2015;64(21):597-8.

4. Centers for Disease C, Prevention. Shigella sonnei outbreak among men who have sex with men--San Francisco, California, 2000-2001. MMWR Morb Mortal Wkly Rep. 2001;50(42):922-6.

5. Hoffmann C, Sahly H, Jessen A, Ingiliz P, Stellbrink HJ, Neifer S, Schewe K, Dupke S, Baumgarten A, Kuschel A, Krznaric I. High rates of quinolone-resistant strains of Shigella sonnei in HIV-infected MSM. Infection. 2013;41(5):999-1003.

6. Morgan O, Crook P, Cheasty T, Jiggle B, Giraudon I, Hughes H, Jones SM. Shigella sonnei outbreak among homosexual men, London. Emerg Infect Dis. 2006;12(9):1458-60.

7. Nelson MR, Shanson DC, Hawkins D, Gazzard BG. Shigella in HIV infection. AIDS. 1991;5(8):1031-2.

8. Pediatrics AAo. *Red Book: Report of the Committee on Infectious Diseases*. 2012. 645-647.

9. Sanford JP, Gilbert DN, Sande MA. *The Sanford guide to antimicrobial therapy*. Antimicrobial Therapy: Dallas, TX. p. volumes.

10. Serafino Wani RL, Filson SA, Chattaway MA, Godbole G. Invasive shigellosis in MSM. Int J STD AIDS. 2015.

11. Baker KS, Dallman TJ, Ashton PM, Day M, Hughes G, Crook PD, Gilbart VL, Zittermann S, Allen VG, Howden BP, Tomita T, Valcanis M, Harris SR, Connor TR, Sintchenko V, Howard P, Brown JD, Petty NK, Gouali M, Thanh DP, Keddy KH, Smith AM, Talukder KA, Faruque SM, Parkhill J, Baker S, Weill FX, Jenkins C, Thomson NR. Intercontinental dissemination of azithromycin-resistant shigellosis through sexual transmission: a cross-sectional study. Lancet Infect Dis. 2015.

12. Bowen A, Hurd J, Hoover C, Khachadourian Y, Traphagen E, Harvey E, Libby T, Ehlers S, Ongpin M, Norton JC, Bicknese A, Kimura A, Centers for Disease C, Prevention. Importation and domestic transmission of Shigella sonnei resistant to ciprofloxacin - United States, May 2014-February 2015. MMWR Morb Mortal Wkly Rep. 2015;64(12):318-20.

13. Centers for Disease C, Prevention. Notes from the field: Outbreak of infections caused by Shigella sonnei with decreased susceptibility to azithromycin--Los Angeles, California, 2012. MMWR Morb Mortal Wkly Rep. 2013;62(9):171.

 Gaudreau C, Barkati S, Leduc JM, Pilon PA, Favreau J, Bekal S. Shigella spp. with reduced azithromycin susceptibility, Quebec, Canada, 2012-2013. Emerg Infect Dis. 2014;20(5):854-6.
Gaudreau C, Ratnayake R, Pilon PA, Gagnon S, Roger M, Levesque S. Ciprofloxacin-resistant Shigella sonnei among men who have sex with men, Canada, 2010. Emerg Infect Dis. 2011;17(9):1747-50. 16. Heiman KE, Karlsson M, Grass J, Howie B, Kirkcaldy RD, Mahon B, Brooks JT, Bowen A, Centers for Disease C, Prevention. Notes from the field: Shigella with decreased susceptibility to azithromycin among men who have sex with men - United States, 2002-2013. MMWR Morb Mortal Wkly Rep. 2014;63(6):132-3.

17. Lane CR, Sutton B, Valcanis M, Kirk M, Walker C, Lalor K, Stephens N. Travel Destinations and Sexual Behavior as Indicators of Antibiotic Resistant Shigella Strains--Victoria, Australia. Clin Infect Dis. 2016;62(6):722-9.

18. Chiou CS, Izumiya H, Kawamura M, Liao YS, Su YS, Wu HH, Chen WC, Lo YC. The worldwide spread of ciprofloxacin-resistant Shigella sonnei among HIV-infected men who have sex with men, Taiwan. Clin Microbiol Infect. 2016;22(4):383 e11-6.

19. Centers for Disease C, Prevention. Antibiotic resistance threats in the United States, 2013. 2013;<u>http://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf</u>.

20. Gupta A, Polyak CS, Bishop RD, Sobel J, Mintz ED. Laboratory-confirmed shigellosis in the United States, 1989-2002: epidemiologic trends and patterns. Clin Infect Dis. 2004;38(10):1372-7.

21. Aragon TJ, Vugia DJ, Shallow S, Samuel MC, Reingold A, Angulo FJ, Bradford WZ. Casecontrol study of shigellosis in San Francisco: the role of sexual transmission and HIV infection. Clin Infect Dis. 2007;44(3):327-34.

22. Centers for Disease C, Prevention. Shigella flexneri serotype 3 infections among men who have sex with men--Chicago, Illinois, 2003-2004. MMWR Morb Mortal Wkly Rep. 2005;54(33):820-2.

23. Ratnayake R, Allard R, Pilon PA. Shifting dominance of Shigella species in men who have sex with men. Epidemiol Infect. 2012;140(11):2082-6.

24. Bowen A GJ, Bicknese A, Campbell D, Hurd J, Kirkcaldy R. Elevated risk of multidrug-resistant Shigella infections among men who have sex with men—United States, 2011–2015. Emerg Infect Dis. 2016;(In Press).

25. Tauxe RV, Johnson KE, Boase JC, Helgerson SD, Blake PA. Control of day care shigellosis: a trial of convalescent day care in isolation. Am J Public Health. 1986;76(6):627-30.

26. Keay R, Singh G, Abdul-Latif M, Rayment M, Nelson M. Shigella flexneri enteritis in risk-taking HIV-infected MSM. J Infect. 2014;68(1):103-4.

27. O'Sullivan B, Delpech V, Pontivivo G, Karagiannis T, Marriott D, Harkness J, McAnulty JM. Shigellosis linked to sex venues, Australia. Emerg Infect Dis. 2002;8(8):862-4.

28. Gilbart VL, Simms I, Jenkins C, Furegato M, Gobin M, Oliver I, Hart G, Gill ON, Hughes G. Sex, drugs and smart phone applications: findings from semistructured interviews with men who have sex with men diagnosed with Shigella flexneri 3a in England and Wales. Sex Transm Infect. 2015;91(8):598-602.

29. Prevention CfDCa. Effectiveness of Prevention Strategies to Reduce the Risk of Acquiring or Transmitting HIV. 2015.

30. Molina J-M, Capitant C, Spire B, Pialoux G, Chidiac C, Charreau I. *On demand PrEP with oral TDF-FTC in MSM: results of the ANRS Ipergay trial.* in *Conference on retroviruses and opportunistic infections.* 2015.

31. Scott HM, Klausner JD. Sexually transmitted infections and pre-exposure prophylaxis: challenges and opportunities among men who have sex with men in the US. AIDS research and therapy. 2016;13(1):1.

32. Volk JE, Marcus JL, Phengrasamy T, Blechinger D, Nguyen DP, Follansbee S, Hare CB. No new HIV infections with increasing use of HIV preexposure prophylaxis in a clinical practice setting. Clinical Infectious Diseases. 2015;61(10):1601-1603.

33. Wolitski RJ. The emergence of barebacking among gay and bisexual men in the United States: a public health perspective. Journal of Gay & Lesbian Psychotherapy. 2005;9(3-4):9-34.

34. Rowniak S. Safe sex fatigue, treatment optimism, and serosorting: New challenges to HIV prevention among men who have sex with men. Journal of the Association of Nurses in AIDS Care. 2009;20(1):31-38.

35. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, Casapía M, Guanira-Carranza JV, Ramirez-Cardich ME. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. New England Journal of Medicine. 2010;363(27):2587-2599.

36. de Wit JB, Adam PC. *Revolution or Evolution? What Can Approaches Based on the Use of Antiretroviral Drugs Contribute to HIV Prevention in Gay Communities in High-Income Countries?*, in *Biomedical advances in HIV prevention*. 2014, Springer. p. 181-204.

37. Holt M, Lea T, Murphy DA, Ellard J, Rosengarten M, Kippax SC, De Wit JB. Australian gay and bisexual men's attitudes to HIV treatment as prevention in repeated, national surveys, 2011-2013. PloS one. 2014;9(11):e112349.

38. Mantell JE, Sandfort TG, Hoffman S, Guidry JA, Masvawure TB, Cahill S. Knowledge and attitudes about Pre-Exposure Prophylaxis (PrEP) among sexually active men who have sex with men (MSM) participating in New York City gay pride events. LGBT health. 2014;1(2):93.

39. Mansergh G, Herbst JH, Mimiaga MJ, Holman J. Preference for condoms, antiretroviral preexposure prophylaxis, or both methods to reduce risk for HIV acquisition among uninfected US Black and Latino MSM. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2015;70(4):e153-e155.

40. Cohen JD, Meenehan SM, MacCabe GS, Groblacher S, Safavi-Naeini AH, Marsili F, Shaw MD, Painter O. Phonon counting and intensity interferometry of a nanomechanical resonator. Nature. 2015;520(7548):522-5.

41. Montaner JS, Lima VD, Harrigan PR, Lourenço L, Yip B, Nosyk B, Wood E, Kerr T, Shannon K, Moore D. Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: the "HIV Treatment as Prevention" experience in a Canadian setting. PloS one. 2014;9(2):e87872.

42. Rhodes SD, Alonzo J, Mann L, Freeman A, Sun CJ, Garcia M, Painter TM. Enhancement of a locally developed HIV prevention intervention for Hispanic/Latino MSM: A partnership of community-based organizations, a university, and the Centers for Disease Control and Prevention. AIDS Education and Prevention. 2015;27(4):312-332.

43. Mansergh G, Miller P, Herbst JH, Mimiaga MJ, Holman J. Effects of Brief Messaging About Undiagnosed Infections Detected through HIV Testing Among Black and Latino Men Who Have Sex With Men in the United States. Sexually transmitted diseases. 2015;42(12):691-693.

44. Underhill K, Morrow KM, Colleran C, Calabrese SK, Operario D, Salovey P, Mayer KH. Explaining the efficacy of pre-exposure prophylaxis (PrEP) for HIV prevention: A qualitative study of message framing and messaging preferences among US men who have sex with men. AIDS and Behavior. 2015:1-13.

45. Mustanski B, Ryan DT, Sanchez T, Sineath C, Macapagal K, Sullivan PS. Effects of messaging about multiple biomedical and behavioral HIV prevention methods on intentions to use among US MSM: results of an experimental messaging study. AIDS and Behavior. 2014;18(9):1651-1660.

46. From the Centers for Disease Control and Prevention. Preliminary FoodNet data on the incidence of foodborne illnesses--selected sites, United States, 2000. JAMA. 2001;285(16):2071-3.

47. Centers for Disease C, Prevention. Preliminary FoodNet data on the incidence of infection with pathogens transmitted commonly through food - 10 states, 2009. MMWR Morb Mortal Wkly Rep. 2010;59(14):418-22.

48. Daskalakis, D. C., & Blaser, M. J. (2007). Another perfect storm: *Shigella* men who have sex with men, and HIV. Clinical Infectious Diseases, 44(3), 335-337.

49. Millett, G. A.Flores, S. A., Peterson, J. L., & Bakeman, R. (2007). Explaining disparities in HIV infection among black and white men who have sex with men: a meta-analysis of HIV risk behaviors. Aids, 21(15), 2083-2091.